Integrating Mass Spectrometry Imaging with Tumor Organoid-Immunity Platform to Identify Metabolic Adaptations in Tumor Immune Resistance
Analytical Chemistry · 2026
DOI: 10.1021/acs.analchem.6c00013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2026. Verfasst von Shiping Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250014, Chi…. Hauptthemen laut MEDLINE: Organoids, Colorectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Qilu University of Technology, National Natural Science Foundation of China.
Abstract (Originalsprache)
Immune evasion limits the efficacy of cancer immunotherapy, yet the metabolic basis underlying differential immune sensitivity remains poorly explored. Here, we established an integrated platform that couples mass spectrometry imaging (MSI) with a patient-derived tumor organoid/immune cell coculture system to delineate metabolic adaptations driving tumor immune resistance. By optimizing a pretreatment workflow that preserves morphological integrity, we achieved in situ MSI mapping of phospholipids, fatty acids, taurine, glutathione, and other metabolites within tumor organoids. Colorectal cancer (CRC) organoids segregate into immune-sensitive and immune-resistant subtypes according to their responses to cocultured peripheral blood mononuclear cells (PBMCs), and the resistant fraction exhibits significantly elevated B7-H3 expression. MSI of these organoids further revealed that phospholipid metabolism is markedly reprogrammed in immune-resistant organoids. This metabolic signature was corroborated by MSI of human CRC tissues, and dynamic MSI of organoids exposed to PBMCs showed that immune-resistant variants preserved a significantly larger phospholipid pool than did their sensitive counterparts, indicating superior membrane-lipid conservation under immune pressure. This integrated MSI-organoid immunity platform offers a broadly applicable framework for dissecting immune-resistance mechanisms and highlights phospholipid metabolism as a potential targetable axis to restore antitumor immunity in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250014, China.
- Second Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
- Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
- Shandong Xinbo Pharmaceutical Research Co., Ltd., Dezhou 251500, China.
ORCID-Profile: Xiao Wang, Chenglong Sun
Förderung
- China Postdoctoral Science Foundation
- Qilu University of Technology
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Shandong University of Traditional Chinese Medicine
Zitieren
APA
Chen, S., Lv, C., Li, Z., Ma, B., Ma, J., Li, M., Zhang, X., Li, M., Zhao, H., Liu, W., Li, Y., Wang, X., Chen, P., & Sun, C. (2026). Integrating Mass Spectrometry Imaging with Tumor Organoid-Immunity Platform to Identify Metabolic Adaptations in Tumor Immune Resistance. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.6c00013
Vancouver
Chen S, Lv C, Li Z, Ma B, Ma J, Li M, et al. Integrating Mass Spectrometry Imaging with Tumor Organoid-Immunity Platform to Identify Metabolic Adaptations in Tumor Immune Resistance. Analytical Chemistry. 2026. doi:10.1021/acs.analchem.6c00013
BibTeX
@article{Chen2026,
author = {Chen, Shiping and Lv, Cancan and Li, Zhichao and Ma, Bangzhen and Ma, Jiwei and Li, Min and Zhang, Xiutong and Li, Mengxuan and Zhao, Hongya and Liu, Wenqian and Li, Yan and Wang, Xiao and Chen, Panpan and Sun, Chenglong},
title = {Integrating Mass Spectrometry Imaging with Tumor Organoid-Immunity Platform to Identify Metabolic Adaptations in Tumor Immune Resistance},
journal = {Analytical Chemistry},
year = {2026},
doi = {10.1021/acs.analchem.6c00013}
}
EUVIMED